CGTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CG

Mkt Cap

$69.3M

Volume

407.46K

Next Earnings

November 5th

Loading chart

CG

CGTXCognition Therapeutics, Inc. Common Stock

CGTX

Pay with—

Available Balance0.00

CG

Mkt Cap

$69.7M

Volume

407.46K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

James M. O’Brien Appointed Chief Financial Officer at MesoblastMesoblast Limited has appointed James M. O'Brien as its US-based Chief Financial Officer to support the company's transition to a fully integrated commercial organization, leveraging his extensive financial management experience in life sciences and biotechnology.GlobeNewswire Inc. · Nov 17, 2025

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.The Motley Fool · Sep 3, 2025

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)Cognition Therapeutics raised $30 million through a registered direct offering of 14.7 million common stock shares at $2.05 per share, with proceeds intended to support Phase 3 development of zervimesine for neurodegenerative disorders.GlobeNewswire Inc. · Sep 2, 2025

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common StockCognition Therapeutics secured a securities purchase agreement to sell 14,700,000 shares, expecting gross proceeds of approximately $30 million. The funds will support Phase 3 programs for zervimesine in neurodegenerative disorders and general corporate purposes.GlobeNewswire Inc. · Aug 28, 2025

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdateCognition Therapeutics reported positive results from its Phase 2 studies of zervimesine (CT1812) in dementia with Lewy bodies (DLB) and Alzheimer's disease. The company plans to advance zervimesine into late-stage trials for these indications.GlobeNewswire Inc. · Mar 20, 2025

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTADCognition Therapeutics presented positive results from a pre-specified analysis of its Phase 2 SHINE study, showing that its drug candidate CT1812 dramatically slowed cognitive decline in Alzheimer's disease patients with lower levels of the biomarker p-tau217.GlobeNewswire Inc. · Oct 29, 2024

Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation OfficeThe Catalyst Accelerator Ogden, in collaboration with the Department of the Air Force Digital Transformation Office, has selected 11 innovative small businesses to address the Air Force's digital modernization challenges through cutting-edge technologies in areas such as AI/ML, data fusion, automation, and cybersecurity.GlobeNewswire Inc. · Aug 23, 2024

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAICPURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer’s Association’s International Conference being held in Philadelphia, PA from July 28-August 1, 2024.GlobeNewswire Inc. · Jul 2, 2024

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's DiseasePURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline.GlobeNewswire Inc. · May 21, 2024

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants -GlobeNewswire Inc. · May 7, 2024

to start trading

CG

CGTXCognition Therapeutics, Inc. Common Stock

CGTX

Pay with—

Available Balance0.00

Your PositionYou don't own any CGTX yet.

Related Tickers

Earnings